CSF1 and renal cell carcinoma: Sunitinib malate (SM) is used to treat patients with gastrointestinal stromal tumours (GISTs), renal cell carcinoma (RCC) and pancreatic neuroendocrine tumours: it is a non-selective inhibitor of targets such as VEGFR 1–3, PDGFR α and β and colony stimulating factor 1 (Chu et al., 2007).